Abstract MRI alterations in the cerebral white (WM) and gray matter (GM) are common in HIV infection, even during successful combination antiretroviral therapy (CART), and their pathophysiology and clinical significance are unclear. We evaluated the association of these alterations with recovery of CD4+ T cells. Seventy-five HIV-infected (HIV+) volunteers in the CNS HIVAnti-Retroviral Therapy Effects Research study underwent brain MRI at two visits. Multi-channel morphometry yielded volumes of total cerebral WM, abnormal WM, cortical and subcortical GM, and ventricular and sulcal CSF. Multivariable linear regressions were used to predict volumetric changes with change in current CD4 and detectable HIV RNA. On average, the cohort (79 % initially on CART) demonstrated loss of total cerebral WM alongside increases in abnormal WM and ventricular volumes. A greater extent of CD4 recovery was associated with increases in abnormal WM and subcortical GM volumes. Virologic suppression was associated with increased subcortical GM volume, independent of CD4 recovery. These findings suggest a possible link between brain alterations and immune recovery, distinct from the influence of virologic suppression. The association of increasing abnormal WM and subcortical GM volumes with C. Fennema-Notestine (*) :
Introduction
Recent neuroimaging studies in HIV-infected individuals demonstrate the continued presence of altered white and gray matter despite effective combination antiretroviral therapy (CART) (Becker et al. 2011a, b; Cardenas et al. 2009; Cohen et al. 2010a, b; Jernigan et al. 2011) , which may reflect events associated with past severe immunosuppression, active virus, immune recovery, and persistent neuroinflammation in the central nervous system (CNS) McArthur et al. 2010) . White matter pathology is reflected in both volume loss and increased abnormalities (e.g., T2 hyperintensities) on structural magnetic resonance imaging (MRI) in HIV infection (Cardenas et al. 2009; Cohen et al. 2010b; Jernigan et al. 2011) . Less white matter volume has been associated with greater past immune suppression (lower nadir CD4+ T cells) (Cohen et al. 2010b; Jernigan et al. 2011 ) and detectable HIV RNA in the cerebrospinal fluid (CSF) (Jernigan et al. 2011) . The association between current immune status (CD4+ T cells) and brain integrity, on the other hand, may be more complex, with higher CD4+ T cell counts related to smaller white matter volumes in one cross-sectional study (Jernigan et al. 2011 ) and complex interactions in association with gray matter volumes (Cohen et al. 2010b) . Subcortical gray matter atrophy also has been reported, particularly within the basal ganglia (e.g., Jernigan et al. 2005; Stout et al. 1998 ) where pathological studies demonstrate high viral load in the caudate nucleus (Anthony et al. 2005; Kumar et al. 2007 ). The pathophysiology and clinical significance of these white matter and subcortical gray matter abnormalities remain unclear in the current era of CART.
One potential source of neuroimaging alterations in CARTtreated HIV-infected (HIV+) individuals is inflammation arising from the recovering immune system. Infrequently, a severe immune reconstitution inflammatory syndrome (IRIS) affects the CNS and is associated with abnormal white matter signal on MRI as well as other alterations, most often in the setting of a secondary opportunistic infection (Johnson and Nath 2010; Murdoch et al. 2007; Sidhu and McCutchan 2010) . But it is unclear whether CNS IRIS represents a unique, idiosyncratic phenomenon that occurs very early in recovery or reflects an extreme inflammatory response on a continuous spectrum of CNS alterations that can occur with immune recovery. MRI measures of abnormal white matter, and T2 hyperintensities in general, may reflect a variety of underlying pathologic processes, including inflammation and gliosis (Awad et al. 1986a (Awad et al. , b, 1987 DeCarli et al. 2005; Fazekas et al. 1993; Jernigan et al. 2011; Spilt et al. 2006; Wen et al. 2009 ). Similar pathological abnormalities have been reported within subcortical regions, particularly in the caudate nucleus and putamen which are known to contain more white matter and vasculature relative to neocortical gray matter (e.g., Berger et al. 2000; Meltzer et al. 1998) . Neuropathological evidence exists for inflammatory processes in the basal ganglia even with successful CART treatment in HIV+ individuals (Anthony et al. 2005; Kumar et al. 2007 ). In fact, recent neuroimaging studies in the current CART era have noted less robust differences in subcortical volumes between HIV+ individuals and seronegative controls, despite continued associations between subcortical volumes and plasma HIV RNA (Cardenas et al. 2009; Cohen et al. 2010b) . One study reported larger rather than smaller putamen volumes in HIV+ individuals, and these larger volumes were associated with higher CD4+ T cell counts (Castelo et al. 2007) . Together these findings suggest that variability in immune response and viral suppression may impact brain integrity in a dynamic manner.
We hypothesized that CD4+ T cell recovery (increasing cell counts over time) would be associated with neuroimaging alterations that may reflect inflammation, including more white matter abnormalities and increased measured volumes of subcortical structures. Very few studies exist on quantitative measures of abnormal white matter in HIV+ individuals (Jernigan et al. 2011) , particularly with respect to longitudinal change. While currently available techniques do not reliably and quantitatively measure abnormalities within gray matter, an increase in such abnormalities within the subcortical gray matter may result in a measured increase in volume (as in Castelo et al. 2007 ); such subcortical gray matter hypertrophy also has been reported in studies of stimulant users presumably related to inflammation (Jacobsen et al. 2001; Jernigan et al. 2005) . We evaluated this hypothesis in a cohort of prospectively studied HIV+ individuals, most CART-treated, with serial MRI and clinical evaluations.
Methods

Study cohort
Participants included 75 HIV+ volunteers from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study, a multicenter, prospective cohort (Table 1) . Participants represented a subset of those previously described in our cross-sectional study (Jernigan et al. 2011) 
Neuromedical assessments
Medical history was gathered, structured medical and neurological examinations were performed, and blood, urine, and CSF (for those who consented to lumbar puncture) samples were collected at initial and follow-up visits. The following clinical parameters were evaluated using structured interviews and laboratory assessments as appropriate: prescription of CART, detectable HIV RNA (viral load), CD4 nadir, current CD4+ T cell count, and serologic evidence of hepatitis C virus (HCV) infection, a common comorbidity that can affect the CNS (Fletcher and McKeating 2012) . Plasma and CSF viral loads were quantified by RT-PCR ultrasensitive assay (nominal lower quantitation limit 50 copies/μL). Nadir CD4+ Tcell count was based on a combination of self-report and medical records. Current CD4+ T cell counts were measured by flow cytometry.
Multi-channel structural MRI protocol
All imaging was performed on General Electric 1.5T scanners that were assessed for quality annually. Four series were acquired for morphometric analysis: Series 1 and 2 were coronal acquisitions with section thickness=2.0 mm, FOV 24 cm, matrix size 256×256: 2D T2-weighted fast spin echo (FSE) with TR=5700 ms, TE=90 ms, ETL=16; and 2D proton density (PD)-weighted FSE with TR=3700 ms, TE=17 ms, ETL=4. Series 3 and 4 were sagittal acquisitions with section thickness=1.3 mm, FOV 24 cm, matrix size 256×256×124: 3D T1-weighted SPGR with TR=20 ms, TE=6 ms, flip angle=30; and 3D PD-weighted SPGR sequence with TR=20 ms, TE=6 ms, flip angle=5.
Because scanner differences (e.g., hardware, software, head coil upgrades) influence neuroimaging metrics (FennemaNotestine et al. 2007; Jernigan et al. 2011) , CHARTER has tracked changes in scanner configuration over time. In the present study, we have included only cases that did not experience a significant change in scanner configuration between visits, and we include a "scanner" variable in statistical analyses (see "Statistical analysis" section) to account for scanner-related effects between sites (Fennema-Notestine et al. 2007; Jernigan et al. 2011) . Importantly, periodic site visits by UCSD staff include MR technician training and the acquisition of human phantom scans, to keep acquisition standards similar across sites.
CHARTER morphometry
As described in Jernigan et al. (2011) , we used the multichannel dataset in a semi-automated workflow optimized to detect subtle changes over time. Primary measures (volumes) include total cerebral white matter and abnormal white matter (e.g., hyperintense regions on T2-weighted images), subcortical (including caudate nucleus, putamen, nucleus accumbens, thalamus, and hypothalamic areas) and cerebral cortical gray matter, ventricular and sulcal CSF, and supratentorial cranial vault to account for individual differences in head size ( Fig. 1 ) (Jernigan et al. 2011) . The workflow includes image inspection for motion and other artifacts, re-slicing to a standard space, intra-subject mutual information (MI) registration (Maes et al. 1997) , bias-correction with nonparametric nonuniformity normalization (N3) (Sled et al. 1998 ), removal of non-brain tissue, three-tissue segmentation (gray matter, white matter, and CSF), abnormal white matter designation, and anatomical labeling performed by trained anatomists. This approach includes the identification of regions of white matter with abnormal MR signal characteristics; these regions segmented as gray matter, but are anatomically located within the white matter. For the longitudinal image processing in the present study, we employed an amplitude-based scaling factor, which accounts for any scale variations in image intensities across visits. To make the scaling robust, since localized regions may exhibit anatomical changes between scans, the scaling parameters were calculated from the difference of the means of the log-transformed (skull-stripped) brain volumes. The follow-up segmentation then was performed with the regression parameters from the first visit, after scaling of image intensities as described above for each sequence individually. Finally, the anatomical labeling for the follow-up visit was created with an algorithm that used tissue segmentations from each visit, anatomical labeling from the first visit, a set of anatomical rules, and an iterative neighborhood voting scheme. The resultant anatomically labeled output dataset reflected underlying tissue changes between visits. The algorithm allows anatomical boundaries to shift between visits due to atrophy, inflammation, or other degenerative and regenerative processes. This preliminary labeling is then reviewed and may be edited by a trained neuroanatomist, within the confines of standard rules.
Statistical analysis
Demographic and clinical characteristics of the cohort were summarized, including an assessment of treatment status and change in CD4+ T cell or virologic suppression. The primary analyses were designed to estimate the degree of association between CD4+ T cell changes and longitudinal change in MRI indices of brain structural integrity, including volumetric measures of subcortical and cortical gray matter, total and abnormal white matter, and ventricular and sulcal (subarachnoid) CSF. All volumetric measures were log-transformed and CD4+ T cell count variables were square root transformed to symmetrize the distributions and stabilize the variances. Change in MRI volumes was calculated as the difference between log-transformed volumes (Time 2−Time 1). An initial comparison was performed simply to examine whether change in volumes was detected across time within this HIV+ cohort, regardless of factors associated with change, using a paired t test comparing volume at Time 1 to volume at Time 2.
To address the main study question for each MRI measure, a series of multivariable linear regression models was used. In every regression model, eight covariates were included to account for variance in MRI measures that were not of primary interest in the present study (as in Jernigan et al. 2011) . These control variables included: age, gender, race/ethnicity, education, time between scans, and scanner. In addition, we controlled for two common neuromedical factors known to influence brain structural integrity (Jernigan et al. 2011) , serologic evidence of HCV and prior history of most severe immunosuppression (nadir CD4+ T cell count), to focus on the effects of the more subtle changes in immune status over time.
Each model was developed to predict change in each MRI measure using a metric of change in measured current CD4+ T cell count across visits. Change in current CD4 was assessed both as a continuous variable, calculated as the difference in square root transformed CD4 count between the two visits, and as a categorical one. The categorical approach used a change cutoff of at least ±50 cells/μL, reflecting numerous published reports showing this degree of CD4 change to be associated with important clinical events (Binquet et al. 2001; Moore et al. 2009; Palella et al. 2003) . Categories of CD4 change included: increasing, decreasing, and minimal change (less than 50 cells) groups which are characterized in Table 2 . Importantly, this regression approach simultaneously examines the independent contribution of changing immune status (CD4 counts) to the change in structural volumes, while controlling for other influences. For example, a significant association between increasing current CD4 and increasing abnormal white matter volume would be the independent contribution of changing immune status, accounting for other influences on abnormal white matter volume such as age, scanner, and nadir CD4. Statistical regression results reported are the t and p values of the parameter estimate specifically associated with the relevant measure of change in current CD4 in predicting volumetric change.
In the final model, we added a variable associated with any change in detectable viral load over this same period, to assess the additional influence of virologic control. That is, regardless of current CD4+ T cell counts, we categorized individuals by whether viral load was detectable (nominal lower quantitation limit 50 copies/μL) over time using four categories: remained undetectable (UND-UND), changed from undetectable to detectable (UND-DET), changed from detectable to undetectable (DET-UND), and remained detectable (DET-DET) viral load levels (Table 3 ). The same regression approach then provides the independent contributions of immune status (current CD4 change) and virologic control (change in detectability of viral load); for the latter, each condition was compared relative to the UND-UND group. We examined plasma HIV RNA for the full cohort and, for a subset of individuals with CSF samples (n=68), we performed the same analysis with detectable CSF HIV RNA over this same period (Table 3) .
Results
Subjects were mostly men (83 %) with a mean age of 45.2 years (Table 1) . At the initial visit, 79 % (n=59) took CART and among those on CART, 69 % (n=41) had achieved virologic suppression in plasma and 83 % (n=49) in CSF; the median duration of the current CART regimen at Time 1 was 11 months [IQR 3, 22] . Over the follow-up period, most subjects (75 %; n=56) remained consistently on CART and 5 % (n=4) initiated CART, while 16 % (n=12) remained off CART and 4 % (n=3) switched off CART. Subjects who maintained or attained virologic suppression on CART at the second visit (n=39) had greater CD4 recovery over the follow-up interval (median change [IQR]=+35 [−37, +98]) than those not taking CART (n=15; −50 [−126, +18]) or those who failed to achieve virologic suppression on CART (n=21; −8 [−172, +103]; Kruskal-Wallis p=0.03).
Over this period of time, the total HIV+ cohort demonstrated significant average loss of total cerebral white matter (t=−5.1, p<0.0001) alongside average increases in ventricular (t=+3.1, p<0.003) and abnormal white matter (t=+5.0, p<0.0001) volumes. There was no significant change in cerebral gray matter (t=+1.1) or sulcal CSF (t=+1.7) volumes, although subcortical gray matter volume tended to increase (t=+2.0, p=0.05). Since we cannot directly link these volumetric changes in our HIV+ cohort to HIV-specific factors based on this comparison alone, we report the subsequent multivariable regression models to examine the impact of immune recovery on brain structure in the context of control covariates.
After adjusting for covariates in a multivariable linear regression model, changes in CD4 cell count between Time 1 and Time 2, considered as a continuous variable, were significantly and positively associated with changes in both abnormal white matter (parameter estimate t=+2.3, p=0.02) and subcortical gray matter (t=+2.3, p=0.03) volumes, but not with change in the other four volumetric measures. We further subdivided the cohort by extent of CD4+ T cell count change over time, using a change cutoff of at least ±50 cells/μL (Binquet et al. 2001; Moore et al. 2009; Palella et al. 2003) ; the three categorical CD4 change groups are characterized in Table 2 . The categorical CD4 change analysis confirmed the findings: there was a significant overall effect for abnormal white matter and subcortical gray matter volumes in the full regression models. The Increasing CD4 group demonstrated greater increases in abnormal white matter (t=+2.9, p=0.006) and subcortical gray matter (t=+2.8, p=0.008) volumes relative to the minimal CD4 group (Fig. 2) . The decreasing CD4 group had significantly greater decreases in subcortical gray matter volumes (t=−2.2, p=0.03) relative to the Minimal CD4 group. There were no significant group differences in total white matter or other measured volumes.
In the final model, inclusion of detectable plasma viral load categories did not change the results of our primary analyses; that is, the Increasing CD4 group remained significantly associated with increasing abnormal white matter (t=3.1, p=0.003) and increasing subcortical gray (t=2.2, p=0.03) volumes. In the decreasing CD4 group, however, subcortical gray matter volume was no longer significantly decreasing (t=−1.44, p=0.16). The distribution of viral load categories across CD4 change groups is presented in Table 3 . Abnormal white matter volume did not differ significantly among the (Fig. 3) . Plasma viral load change categories, however, were associated with subcortical gray matter ( Fig. 3) and fluid measures. For those changing from detectable to undetectable plasma viral load (DET-UND), subcortical gray matter volumes increased (t=+2.8, p=0.008).
In contrast, for those changing from undetectable to detectable viral load (UND-DET), CSF volumes decreased (ventricles t=−2.0, p=0.05; sulcal CSF t=−2.3, p=0.02); subcortical gray matter volume did not change significantly (t=−1.8, p>0.10).
For the group remaining detectable over time (DET-DET), ventricular volume increased (t=+3.9, p=0.0003) suggestive of greater atrophy over time. For Detectable CSF viral load categories (n=68), similar findings of increased subcortical volumes for DET-UND (t=+2.3, p=0.02) and greater atrophy for DET-DET (ventricles t=+2.3, p=0.03) were demonstrated.
Discussion
We found that during CART, recovery of CD4+ T cells was significantly associated with increases in abnormal white matter burden and in the volume of subcortical gray matter, even while controlling for variables such as nadir CD4. CD4+ T cell increases of at least 50 cells/μL, a clinically meaningful degree of change (Binquet et al. 2001; Moore et al. 2009; Palella et al. 2003) , were seen in about 1/3 of subjects, and these subjects had the largest increases in abnormal white matter and subcortical gray matter volumes. By contrast, change in plasma viral suppression was not independently associated with abnormal white matter volume, although those changing from detectable to undetectable levels did show an increase in subcortical gray matter volumes, independent of the change in CD4. Taken together, these findings suggest a link between regional brain alterations and immune recovery, and a separate impact of virologic suppression on the brain. Supporting the expected association between immune recovery and CART, we found greater CD4 gains among subjects initiating a new CART regimen or maintaining stable treatment than among those not taking CART or discontinuing it between visits. The median duration of an individual's current CART regimen at the initial visit was less than 1 year, and over three quarters of our subjects remained on or initiated CART over the period of study. Since previous studies have shown clinically relevant CD4 recovery for up to several years after CART initiation (Koletar et al. 2004) , these CD4 increases were likely CART induced. The differences between immunologic and virologic changes in predicting MRI alterations here may be clinically important for two reasons. First, virologic changes are most pronounced during the first 3 months after CART initiation. Since most of our subjects had already been on their CART regimens for about 1 year, and only four initiated a new regimen between visits, viral load changes seen in this study were generally modest. Thus, some of our MRI findings may not generalize to subjects who have very recently initiated CART. Second, discordant virologic and immunologic changes on CART have been previously shown in a substantial minority of individuals (Goicoechea et al. 2006; Schechter and Tuboi 2006) . For example, in one series of 404 patients initiating a new CART regimen, only 70.5 % experienced favorable concordant responses, defined as an increase in CD4 count of ≥50 cells/μL and achievement of undetectable plasma HIV RNA level (Tan et al. 2008) .
The pathophysiology and clinical correlates of white matter abnormalities and other MR alterations in HIV infection are incompletely understood, and the differences in recovery of white matter and subcortical gray matter may be important clinically. Previous cross-sectional studies have reported that abnormal white matter in HIV+ individuals was associated with lower nadir CD4 (Jernigan et al. 2011 ), while higher current CD4+ T cell counts have been associated with larger putamen volumes (Castelo et al. 2007 ) and smaller overall subcortical gray matter volumes (Jernigan et al. 2011) . Longitudinal studies, such as the current report, offer the opportunity to examine these neurological abnormalities as they evolve during immune recovery and treatment, potentially yielding insights into pathogenesis. We and others have previously evaluated longitudinal MR changes in the pre-CART era (Stout et al. 1998) , demonstrating gray and white matter tissue loss over time, while only a few studies have examined longitudinal change among patients on CART, emphasizing continued loss in overall white matter (Cardenas et al. 2009 ). The present study uniquely reports quantitative change in abnormal white matter in HIV+ individuals and suggests that subtle, possibly inflammatory changes may be evident on MRI over relatively short periods of time, particularly within white and subcortical gray matter tissues, and emphasizes the importance of measuring abnormalities within these regions.
Although CD4+ T cell and brain MR changes were contemporaneous, causal relationships cannot be inferred from our findings. Nevertheless, some consideration of potential causal mechanisms is warranted to guide future hypothesis testing and study design. Known sources of abnormal white matter include vasogenic edema, astroglial proliferation, inflammatory infiltrates, injury to axons or myelin, and microvascular ischemia (Awad et al. 1986a (Awad et al. , b, 1987 DeCarli et al. 2005; Fazekas et al. 1993; Spilt et al. 2006; Wen et al. 2009 ). Relevant to these potential mechanisms, we found that increasing burden of white matter abnormalities occurred in the context of general reductions in white matter volume. Since vasogenic edema (characterized by excess interstitial water), astroglial proliferation, and inflammatory cell infiltration of white matter likely would drive increased rather than decreased white matter volume, these mechanisms cannot solely explain the findings. Injury to myelin and microvascular ischemia, on the other hand, might yield tissue destruction and reduced volume. Future studies could improve our understanding of brain changes in HIV infection by investigating whether one or a combination of these mechanisms underlies the increased burden of white matter abnormalities we observed with CD4 recovery on CART. Mechanisms underlying increases in subcortical gray matter volumes might include increased tissue water content or inflammatory cell infiltration, as suggested in recent studies of methamphetamine abuse (Chang et al. 2005; Jernigan et al. 2005) .
It is possible and even likely that the structural MRI changes seen in this study are transient and may resolve once CD4 recovery has plateaued. Although HIV viral suppression typically is completed during the first 3 months of CART initiation, immune recovery lags and may continue for years (Koletar et al. 2004 ). Recovery of brain abnormalities could be the anatomic manifestation associated with functional (cognitive) recovery in many patients who initiate CART which also may continue for many years (McCutchan et al. 2007 ). Future studies should examine neuroimaging volumes at more timepoints to better assess the evolution of change over time. Additional association studies will shed light on both the potential inflammatory underpinnings, including examination of CSF inflammatory biomarkers (e.g., MCP-1), and the functional significance of these changes, examining the impact of MR changes on neurocognitive functioning, mood, and other clinically important factors.
